Mr. Jeysman served as President of Ferring Inc. Canada from 1995 until 2012, where he was responsible for all pharmaceutical operations in Canada. During his time with Ferring, he built the company into a leading specialty company valued at $100 million of products, ranked in the top 50 pharmaceutical companies in Canada. Before starting Ferring Canada, he held progressive management positions with Sterling Drug Ltd.

At Ferring, Mr. Jeysman oversaw many development projects. Most noteworthy was the development of carbetocin; a long-acting synthetic peptide analogue of oxytocin with agonist properties. A total of 18 studies were completed at Canadian university sites and laboratories that provided a full development program including pharmacology, pharmacokinetics, clinical (phase 1-3), chemistry, and quality/stability and manufacturing studies. Carbetocin is now approved and marketed in 35 countries indicated in the management of postpartum bleeding following elective C section and vaginal delivery.

Impressed with landmark research conducted by Dr. Laurence Klotz (Sunnybrook), Mr. Jeysman came out of retirement and founded KVR Pharmaceuticals Inc. in 2016. KVR’s mission is to develop products for treatment within the bleeding disorder market and related disease. Molecules involved in the coagulation pathway are important in other biological mechanisms including cancer. KVR’s emerging research reveals the potential to slow cancer spread, reduce recurrence, and improve quality of life for patients suffering from aggressive cancers.

He also serves on the Board of Directors for a number of Canadian organizations. Mr. Jeysman has actively participated in numerous medical advisory boards and is viewed as a key opinion and thought- leader with extensive knowledge across several therapeutic areas.